van Halteren Astrid G S, Dierselhuis Miranda P, Netelenbos Tanja, Fechter Mirjam
Immunology Laboratory; Willem Alexander Children's Hospital/Leiden University Medical Center; Leiden, the Netherlands.
Department of Pediatrics; Willem Alexander Children's Hospital/Leiden University Medical Center; Leiden, the Netherlands.
Chimerism. 2014;5(2):56-8. doi: 10.4161/chim.29562.
Allogeneic hematopoietic stem cell transplantation (HSCT) is a widely applied treatment for disorders mainly involving the hematopoietic system. The success of this treatment depends on many different patient- and donor-specific factors. Based on higher CD34+ yields and superior clinical outcomes associated with the use of male donors, males are generally seen as the preferred HSCT donor. In addition, female donors are notorious for bearing memory type lymphocytes induced by previous pregnancies; such alloimmune cells may provoke unwanted immune reactions such as graft-vs.-host disease in transplant recipients. Consequently, many transplant centers try to avoid parous donors, particularly when searching the best unrelated donor for a male patient. We recently showed that parous women with female offspring have an anti-male directed tolerogenic immune status comparable to that of nulliparous donors. As discussed in this article addendum, the sex of the donor's offspring combined with the presence of HY-specific T regulator cells are possibly better selection criteria than parity status per se.
异基因造血干细胞移植（HSCT）是一种广泛应用于主要涉及造血系统疾病的治疗方法。这种治疗的成功取决于许多不同的患者和供体特异性因素。基于使用男性供体时更高的CD34+产量和更好的临床结果，男性通常被视为首选的HSCT供体。此外，女性供体因携带先前妊娠诱导的记忆型淋巴细胞而声名狼藉；此类同种免疫细胞可能会在移植受者中引发不必要的免疫反应，如移植物抗宿主病。因此，许多移植中心试图避免选择有生育史的供体，尤其是在为男性患者寻找最佳无关供体时。我们最近发现，有女性后代的经产妇具有与未生育供体相当的抗男性定向耐受性免疫状态。如本文附录中所讨论的，供体后代的性别与HY特异性调节性T细胞的存在可能是比生育状态本身更好的选择标准。
